| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Animal Protocol |
This study did not involve the administration of pseudouridine as a drug to animals. It used yeast strains and cultured human HeLa cells. Yeast strains (wild-type and various pus and snoRNA deletion mutants) were grown in YPAD medium at 30°C and harvested by centrifugation either in log phase (OD ~1) or at high density (OD ~12-15). HeLa cells were cultured in DMEM with 10% FBS at 37°C with 5% CO₂. For serum starvation experiments, cells were plated, washed, and then incubated in either serum-free medium or full medium for 24 hours [1].
|
|---|---|
| References | |
| Additional Infomation |
Pseudouridine is a C-glycopyrimidine compound composed of uracil linked to a β-D-furanose ribose residue at the 5-position. It is the C-glycosyl isomer of the nucleoside uridine and is an important metabolite. Pseudouridine is a metabolite found or produced in Escherichia coli (strains K12 and MG1655). It has been reported in Drosophila melanogaster, Mycoplasma gallisepticum, and other organisms with relevant data. β-Pseudouridine is a metabolite found or produced in Saccharomyces cerevisiae. It is a naturally occurring uridine isomer in RNA, where the ribosome is attached to a carbon atom instead of a nitrogen atom.
|
| Molecular Formula |
C9H12N2O6
|
|---|---|
| Molecular Weight |
244.203
|
| Exact Mass |
244.069
|
| CAS # |
1445-07-4
|
| PubChem CID |
15047
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
598.4±60.0 °C at 760 mmHg
|
| Melting Point |
231 °C(dec.)
|
| Flash Point |
315.7±32.9 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.697
|
| LogP |
-3.77
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
382
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O1[C@]([H])(C([H])([H])O[H])[C@]([H])([C@]([H])([C@]1([H])C1=C([H])N([H])C(N([H])C1=O)=O)O[H])O[H]
|
| InChi Key |
PTJWIQPHWPFNBW-GBNDHIKLSA-N
|
| InChi Code |
InChI=1S/C9H12N2O6/c12-2-4-5(13)6(14)7(17-4)3-1-10-9(16)11-8(3)15/h1,4-7,12-14H,2H2,(H2,10,11,15,16)/t4-,5-,6-,7+/m1/s1
|
| Chemical Name |
5-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrimidine-2,4-dione
|
| Synonyms |
Pseudouridine NSC-162405 NSC162405NSC 162405
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~511.88 mM)
H2O : ~25 mg/mL (~102.38 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (8.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 25 mg/mL (102.38 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0950 mL | 20.4750 mL | 40.9500 mL | |
| 5 mM | 0.8190 mL | 4.0950 mL | 8.1900 mL | |
| 10 mM | 0.4095 mL | 2.0475 mL | 4.0950 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04641559 | COMPLETED | Other: Personalized nutrition group Other: Personalized Plan group Other: Control group |
Dietary Habits Health Status Personalized Nutrition |
Technological Centre of Nutrition and Health, Spain | 2020-12-09 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
